Analysts' ratings for Ocular Therapeutix OCUL over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $14.0, along with a high estimate of $22.00 and a low estimate of $7.00. This current average represents a 3.45% decrease from the previous average price target of $14.50.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Ocular Therapeutix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yi Chen | HC Wainwright & Co. | Maintains | Buy | $14.00 | $14.00 |
| Biren Amin | Piper Sandler | Maintains | Overweight | $15.00 | $15.00 |
| Tara Bancroft | TD Cowen | Raises | Buy | $11.00 | $7.00 |
| Joseph Catanzaro | Piper Sandler | Maintains | Overweight | $15.00 | $15.00 |
| Yi Chen | HC Wainwright & Co. | Maintains | Buy | $14.00 | $14.00 |
| Yi Chen | HC Wainwright & Co. | Lowers | Buy | $14.00 | $16.00 |
| Jonathan Wolleben | JMP Securities | Lowers | Market Outperform | $22.00 | $24.00 |
| Tara Bancroft | TD Cowen | Lowers | Hold | $7.00 | $11.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ocular Therapeutix. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ocular Therapeutix's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ocular Therapeutix's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Ocular Therapeutix analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Ocular Therapeutix's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.47%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocular Therapeutix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -438.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -25.99%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.4%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Ocular Therapeutix adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
